SIGA - SIGA Corp Year-over-year net earnings per share growth for the last 12 months

Graphic logo of SIGA Technologies, Inc. (SIGA)

SIGA Technologies, Inc. (SIGA) generates revenue through biosecurity deals, where the primary driver is the sale of TPOXX to strategic national stockpiles. The quarterly EPS change scale on GURU.Markets reflects profit dynamics, while 54.20 characterizes this valuation parameter. Management is successfully executing long-term obligations as it pursues global expansion. Multi-year government agreements for the supply of antiviral agents ensure revenue stability.

SIGA Technologies (SIGA) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 11/16/2026

Summary analytical data breakdowns for SIGA Technologies, Inc. (SIGA)

- market value and analyst target forecast:
- market capitalization statistics:
Fundamental company analysis:SIGA Technologies Inc - SIGA
Flagship merchandise of TPOXX

Long-term capital requires strict volatility control and confirmation of earnings sustainability. For biodefense leader SIGA Technologies, Inc. (SIGA), which invests in antiviral R&D, stable cash flows are critical. The quarterly EPS dynamics reflect the percentage change in net income per share relative to the previous period. Growth in this indicator confirms the effectiveness of innovation commercialization. A stable trend minimizes the risk of drawdowns during macroeconomic shocks.

Competitor analysis

Gilead Sciences Inc (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth curevac.com|Year-over-year earnings per share growth for the last twelve months Valneva Corp (VALN)|Year-over-year earnings per share growth for the last twelve months VIR (Vir Biotechnology)|Year-over-year earnings per share growth for the last twelve months Emergent Bio EBS|Quarterly EPS earnings growth Atea Pharmaceuticals AVIR|IVVD - Year-over-year earnings per share growth for the last twelve months|ENTA (Enanta Pharmaceuticals) - Year-over-year earnings per share growth for the last 12 months|INO (Inovio) - Year-over-year net earnings per share growth for the last 12 months|HLVX (HilleVax Inc) - Year-over-year earnings per share growth for the last twelve months|KLRS (Kalaris Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year net earnings per share growth for the last 12 months NNVC (NanoViricides)|TLPH (Talphera, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cocrystal Pharma Inc COCP|Year-over-year earnings per one share growth for the last 12 months TRAW|Dogwood Therapeutics Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Qualigen Corp|ALVR (AlloVir Bio) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VBI Vaccines, Inc.|VIRI (virios.com) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart, Inc.)